Kogelberg, H; Miranda, E; Burnet, J; Ellison, D; Tolner, B; Foster, J; Picón, C; ... Chester, K; + view all Kogelberg, H; Miranda, E; Burnet, J; Ellison, D; Tolner, B; Foster, J; Picón, C; Thomas, GJ; Meyer, T; Marshall, JF; Mather, SJ; Chester, K; - view fewer (2013) Generation and Characterization of a Diabody Targeting the αvβ6 Integrin. PLoS One , 8 (9) , Article e73260. 10.1371/journal.pone.0073260.

Preview

PDF journal.pone.0073260.pdf Download (3MB)

Abstract

The αvβ6 integrin is up-regulated in cancer and wound healing but it is not generally expressed in healthy adult tissue. There is increasing evidence that it has a role in cancer progression and will be a useful target for antibody-directed cancer therapies. We report a novel recombinant diabody antibody fragment that targets specifically αvβ6 and blocks its function. The diabody was engineered with a C-terminal hexahistidine tag (His tag), expressed in Pichia pastoris and purified by IMAC. Surface plasmon resonance (SPR) analysis of the purified diabody showed affinity in the nanomolar range. Pre-treatment of αvβ6-expressing cells with the diabody resulted in a reduction of cell migration and adhesion to LAP, demonstrating biological function-blocking activity. After radio-labeling, using the His-tag for site-specific attachment of (99m)Tc, the diabody retained affinity and targeted specifically to αvβ6-expressing tumors in mice bearing isogenic αvβ6 +/- xenografts. Furthermore, the diabody was specifically internalized into αvβ6-expressing cells, indicating warhead targeting potential. Our results indicate that the new αvβ6 diabody has a range of potential applications in imaging, function blocking or targeted delivery/internalization of therapeutic agents.

Download activity - last month

Export as XMLJSONCSV

Download activity - last 12 months

Export as CSVXMLJSON

Downloads by country - last 12 months

Export as JSONXMLCSV

Archive Staff Only

View Item